JP Patent

JP2022184898A — 転移期前立腺癌を治療する方法

Assigned to Ferring International Center SA · Expires 2022-12-13 · 3y expired

What this patent protects

【課題】対象の転移期前立腺癌の治療のための組成物を提供する。 【解決手段】デガレリクスを含む組成物。 【選択図】図１

USPTO Abstract

【課題】対象の転移期前立腺癌の治療のための組成物を提供する。 【解決手段】デガレリクスを含む組成物。 【選択図】図１

Drugs covered by this patent

Patent Metadata

Patent number
JP2022184898A
Jurisdiction
JP
Classification
—
Expires
2022-12-13
Drug substance claim
No
Drug product claim
No
Assignee
Ferring International Center SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.